Study suggests timing triple-negative breast cancer drug 5-FU administration based on circadian rhythm for improved outcomes.

A study from Charite-Universitatsmedizin Berlin suggests that timing cancer medication administration based on a patient's circadian rhythm could significantly impact treatment outcomes. The researchers identified that triple-negative breast cancer cells are most responsive to chemotherapeutic drug 5-FU between 8 and 10 a.m. Their findings could pave the way for personalized cancer treatments based on individual circadian rhythms. More research is needed to validate the study results.

August 26, 2024
20 Articles